Movement Alert｜REVVITY INC Rises 5.21% in Regular Trading, Acquisition of Human Cell Design Continues to Boost Market Sentiment

Market Focus

1 hour ago

On September 16, REVVITY INC rose 5.21% in regular trading, trading at $147.24/share, with turnover of $39.50 million. The stock hit a fresh 52-week high, extending the prior session's surge of over 9%.

The sustained rally is driven by the company's recently announced acquisition of French biotech firm Human Cell Design (HCD), which specializes in developing human cell models for metabolic diseases such as diabetes and obesity. Upon completion, HCD's human pancreatic beta-cell models will be integrated into Revvity's Life Sciences portfolio, enhancing its drug discovery and screening capabilities for GLP-1 and other metabolic disease therapies while expanding applications in regenerative medicine and cell therapy. The transaction is expected to close in the fourth quarter, pending regulatory approval; financial terms were not disclosed.

Within the Life Sciences Tools & Services sector, the broader group saw mixed gains. Among peers, Illumina rose 5.98%, Tempus AI gained 2.44%, Mettler-Toledo advanced 2.37%, Thermo Fisher Scientific added 1.07%, and Danaher climbed 0.75%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg.tigerfiesta.com/news/1116060609"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1116060609\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1116060609?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-16 21:45","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1116060609","market":"us","top_or_hot":-1,"title":"Movement Alert｜REVVITY INC Rises 5.21% in Regular Trading, Acquisition of Human Cell Design Continues to Boost Market Sentiment","media":"Market Focus","content":"<p><p>On September 16, REVVITY INC rose 5.21% in regular trading, trading at $147.24/share, with turnover of $39.50 million. The stock hit a fresh 52-week high, extending the prior session's surge of over 9%.</p><p>The sustained rally is driven by the company's recently announced acquisition of French biotech firm Human Cell Design (HCD), which specializes in developing human cell models for metabolic diseases such as diabetes and obesity. Upon completion, HCD's human pancreatic beta-cell models will be integrated into Revvity's Life Sciences portfolio, enhancing its drug discovery and screening capabilities for GLP-1 and other metabolic disease therapies while expanding applications in regenerative medicine and cell therapy. The transaction is expected to close in the fourth quarter, pending regulatory approval; financial terms were not disclosed.</p><p>Within the Life Sciences Tools & Services sector, the broader group saw mixed gains. Among peers, Illumina rose 5.98%, Tempus AI gained 2.44%, Mettler-Toledo advanced 2.37%, Thermo Fisher Scientific added 1.07%, and Danaher climbed 0.75%.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜REVVITY INC Rises 5.21% in Regular Trading, Acquisition of Human Cell Design Continues to Boost Market Sentiment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜REVVITY INC Rises 5.21% in Regular Trading, Acquisition of Human Cell Design Continues to Boost Market Sentiment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-09-16 21:45</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On September 16, REVVITY INC rose 5.21% in regular trading, trading at $147.24/share, with turnover of $39.50 million. The stock hit a fresh 52-week high, extending the prior session's surge of over 9%.</p><p>The sustained rally is driven by the company's recently announced acquisition of French biotech firm Human Cell Design (HCD), which specializes in developing human cell models for metabolic diseases such as diabetes and obesity. Upon completion, HCD's human pancreatic beta-cell models will be integrated into Revvity's Life Sciences portfolio, enhancing its drug discovery and screening capabilities for GLP-1 and other metabolic disease therapies while expanding applications in regenerative medicine and cell therapy. The transaction is expected to close in the fourth quarter, pending regulatory approval; financial terms were not disclosed.</p><p>Within the Life Sciences Tools & Services sector, the broader group saw mixed gains. Among peers, Illumina rose 5.98%, Tempus AI gained 2.44%, Mettler-Toledo advanced 2.37%, Thermo Fisher Scientific added 1.07%, and Danaher climbed 0.75%.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"RVTY","symbol_name":"REVVITY INC","start_time":0,"source_url":"","article_id":"1116060609","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1116060609","pubTimestamp":1789566344,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On September 16, REVVITY INC rose 5.21% in regular trading, trading at $147.24/share, with turnover of $39.50 million. The stock hit a fresh 52-week high, extending the prior session's surge of over...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"RVTY":"REVVITY INC"},"translate_title":"走势警报|REVVITY INC 常规交易上涨 5.21%，收购 Human Cell Design 继续提振市场情绪","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RVTY":1},"content_text":"On September 16, REVVITY INC rose 5.21% in regular trading, trading at $147.24/share, with turnover of $39.50 million. The stock hit a fresh 52-week high, extending the prior session's surge of over 9%.The sustained rally is driven by the company's recently announced acquisition of French biotech firm Human Cell Design (HCD), which specializes in developing human cell models for metabolic diseases such as diabetes and obesity. Upon completion, HCD's human pancreatic beta-cell models will be integrated into Revvity's Life Sciences portfolio, enhancing its drug discovery and screening capabilities for GLP-1 and other metabolic disease therapies while expanding applications in regenerative medicine and cell therapy. The transaction is expected to close in the fourth quarter, pending regulatory approval; financial terms were not disclosed.Within the Life Sciences Tools & Services sector, the broader group saw mixed gains. Among peers, Illumina rose 5.98%, Tempus AI gained 2.44%, Mettler-Toledo advanced 2.37%, Thermo Fisher Scientific added 1.07%, and Danaher climbed 0.75%.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}